{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Antibody Drug Conjugates: New Weapons Against Cancer

Activity Steps

Purpose of Activity

To provide information on antibody drug conjugates (ADCs) that have been approved by the Food & Drug Administration (FDA).

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Evaluate the use of antibody drug conjugates (ADCs) for patients with advanced/metastatic disease.
  2. Describe the indications for those ADCs that are currently available.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT0320
Published: March 2020
Expires: 3/4/2022
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Rebecca Wilson